Shots:
- Isofol to receive $100M as up front, development, regulatory and commercial milestones, and clinical development cost and is eligible to receive royalties on sales of the therapy and retain its right to the therapy in ROW
- Solasia will lead clinical development activities in Japan and will be responsible for registrational filing and approval in the licensed territory. The collaboration will initially focus on the development and commercialization of arfolitixorin as 1L treatment for mCRC patients and may extend it to other indications
- Arfolitixorin is currently being evaluated in the ongoing global P-III AGENT study, conducted in the US, Canada, EU, Australia, and Japan. Isofol and Solasia plan to expand the study with additional sites in Japan while Isofol will remain as global sponsor of the study
Click here to read full press release/ article | Ref: Isofol | Image: CNN
